

MONTHLY HOUSE VIEWS

March 2020



Growth Backtracks for Now

Macro

In recent days, the coronavirus epidemic has spread more widely beyond China's borders, raising fears of a hit to global growth. At the same time the rate of progression of the virus in China has slowed, enabling many companies to reopen offices and factories, although not yet at full capacity. We expect a sharp slowdown in China's output in the first quarter, followed by a pickup from Q2. In other countries, outbreaks of the virus are likely to be met with the same measures as in China – quarantine, travel restrictions, factory closures etc. – meaning that the impact on their growth may continue into the second quarter, before recovery takes hold.

Central Banks

Market expectations for US Federal Reserve (Fed) rate cuts have risen in recent days in response to the unfolding epidemic. We expect policy-makers to be on high alert for any deepening of risks but they may hesitate to cut in the short term. The European Central Bank (ECB) remains unlikely to cut rates further into negative territory and may prefer to boost its asset purchases if called on to ease policy. The Peoples' Bank of China (PBoC) has cut a number of its key rates and stands ready to ease further were the return to work to be delayed again. Other emerging world central banks have followed suit, taking advantage of current low inflation levels.

Markets

After a period of resilience, western world equity markets have sold off in recent days as the coronavirus spread beyond China, a typical reaction to such outbreaks. On the other hand, Chinese equities have begun to outperform as the number of new cases of the disease there showed signs of peaking. We expect global stock markets to recover lost ground once the epidemic begins to come under control. Safe havens such as G7 government bonds, gold and the US dollar have provided useful diversification. However, we suggest more caution on lower-quality higher-yielding (HY) corporate bonds – issuers may face cash-flow problems as the crisis drags on.

Bottom line

We suggest keeping a broadly diversified approach to portfolio construction, with a focus on safe-havens such as fixed-income and gold, which remains our preferred diversification tool. Given the risks to credit quality in HY bonds, we propose locking in some profits to reduce exposure. We suggest keeping a Neutral stance on global equities given the short-term risks but remain confident that markets should rally in the medium-term once better news about the coronavirus outbreak emerges. Similarly, Brent prices should rally back towards our target \$60-70 range by year-end.

In accordance with the applicable regulation, we inform the reader that this material is qualified as a marketing document. CA09/H1/2020

OUR ASSET ALLOCATION

The table below presents the latest conclusions of our Global Investment Committee

		Summary house views					
		Strong UW	UW	N	OW	Strong OW	Change since last GIC
EQUITY	GLOBAL EQUITY						
	United States						
	Eurozone						
	United Kingdom						
	Japan						
	Emerging						
FIXED INCOME	SOVEREIGN						
	GLOBAL RATES						
	U.S. Treasuries						
	U.S. Breakeven						
	Bunds						
	EMU Breakeven						
	Gilts						
	Gilts Breakeven						
	JGBs						
	EM Govies (\$)						
	CORPORATE						
	U.S. IG						
	U.S. HY						-
EMU IG							
EMU HY						-	
UK IG							
UK HY							
Duration USD*							
Duration EUR*							
Duration GBP*							
FOREX	EURUSD						
	USDJPY						
	GBPUSD						
	EURCHF						
	EM FX (vs. USD)						
COMDTY	Brent						+
	Gold						
ALTERNATIVE	ALT. STRATEGIES						
	L/S Equity						
	Event-Driven						
	FI Arbitrage						
	Global Macro / CTAs						

O/W Positioning
 Overweight
 N Neutral
 U/W Underweight

*Duration
 Long – 7-10 years
 Intermediate – 5-7 years
 Short – 3-5 years

EQUITIES

United States	Despite the recent sell-off, demanding valuations should limit the upside for US equities this year. We remain Neutral.
Europe	The coronavirus epidemic has continued to depress market sentiment, especially once international contagion began to accelerate in the second half of February. We remain Neutral.
Eurozone	Coronavirus fears have overwhelmed the improvement in various measures of business confidence. We are Neutral.
UK	Given the cross-currents at work, we remain Neutral.
Switzerland	Swiss equities have demonstrated resilience. However, the Swiss franc has strengthened on safe-haven inflows. We suggest a Neutral stance.
Japan	Despite attractive valuations, poor economic data and coronavirus risks suggest a Neutral stance.
Emerging (EM)	Chinese equities have demonstrated resilience as new Covid-19 cases begin to slow and valuations are attractive. We are Overweight.

FIXED INCOME

Sovereigns	Until the epidemic provides reassuring signs of containment, it is unlikely we will see much upside in sovereign yields, as investors flock to safe havens.
Duration*	We prefer intermediate maturities in the US and shorter-dated bonds in EUR and GBP. In the near-term, 10-year US rates can provide some diversification against volatility spikes.
Inflation-linked	Given attractive valuations, we remain Overweight on US inflation contracts (“breakevens”).
Investment Grade	Given the current macroeconomic backdrop, we still prefer better quality corporate bonds.
High Yield	While we assume growth and markets will eventually recover, uncertainty is set to linger for now. In the near term, we expect rates to stay low and riskier credit to suffer. We therefore turn tactically cautious on High Yield.
Emerging debt (in € and \$)	For now, we see expect EM debt markets to continue to deliver positive returns given attractive valuations and supportive fundamentals.

CURRENCIES

EUR/USD	Rising expectations of Fed rate cuts have served to weaken the perceived yield advantage of the dollar over the euro. We expect modest upside in EUR/USD by year-end.
GBP/USD	We expect sterling to rally back above \$1.35\$ once uncertainties about EU-UK negotiations are lifted.
EUR/GBP	As negotiations on future relations between the UK and the EU start, we don’t expect major moves in coming months.
USD/JPY	Given disappointing economic data and its safe-haven role, the yen should continue to trade in a relatively narrow range against the US dollar.
EUR/CHF	Any sustained weakening in the franc against the euro will need confirmation that the Wuhan flu outbreak has been contained. We remain Neutral.
Emerging	A recovery in EM currencies is unlikely before the epidemic comes under control and safe-haven buying of the dollar peters out.

ALTERNATIVES

Hedge funds	Within hedge funds, Fixed Income Arbitrage should benefit from the bull run in rates while Event Driven is set to recover once the Wuhan flu scare abates.
Gold	Gold should continue to provide useful safe-haven benefits.
Oil	Oil prices should recover by year-end and we suggest moving Overweight.

Source: SGPB, 28/02/2020

* Duration: short = 3-5 years, medium = 5-7 years, long = 7-10 years

HY = High Yield bonds (higher return but greater risks), IG = Investment Grade bonds (higher quality but lower return)

ECONOMIC OUTLOOK

Ill at ease

The near-term outlook for global economies will be heavily affected by prudential measures taken to stem the spread of the coronavirus epidemic. While the crisis appears to be coming under control in China, outbreaks elsewhere must be dealt with. A recovery in global output has probably been postponed to the second half of 2020, and 2021.

If markets had been somewhat complacent to the economic threats posed by the coronavirus, late February saw them scrambling to reassess the risks. Following all-time highs for global equities in mid-month, MSCI's All-Country World index has declined 10%. In that time, safe-haven assets surged: gold hit its highest level since the Eurozone debt crisis and US government bond yields plunged to record lows. All-time equity market highs followed by a sharp sell-off suggest investors grappling to accurately price an epidemiological outcome which is unknowable, particularly in the short-term.

The recent spread of the coronavirus epidemic in major global economies such as South Korea and Italy, where some 52,000 people in the north face travel restrictions, has caused a reassessment of global risks. Economic data is already beginning to reflect diminished activity levels. Oil prices have fallen to levels last seen during peak trade-war fears in December 2018. In the US, Markit's preliminary manufacturing and services purchasing manufacturers indices (PMIs) for February fell compared with January – final figures to be released in early March may well be worse. In China, there has been renewed downward pressure on the Chinese yuan versus the US dollar since mid-February. Moreover, it is inevitable that some economic activity, particularly in areas such as travel and leisure, is lost forever, not merely delayed.


However, there are other important considerations. Eurozone preliminary PMIs for February were better than expected, and above figures from January. The UK's preliminary PMIs are unequivocally showing surging economic sentiment, with the manufacturers reporting the fastest rise in output in ten months.

Moreover, while the spread of the virus beyond China is troubling, the growth rate of confirmed cases appears to be declining in mainland China, enabling the situation to start to normalize at its epicentre: most car plants are reported to have reopened; passenger traffic remains low but migrant flows into major cities have rebounded; coal consumption has started to pick up; container ship activity has almost recovered to normal levels. Only hindsight will tell if the worst is indeed behind us, but there are some signs of stabilisation.

We expect macro data to worsen in coming weeks as the economic impact of China's draconian measures – quarantines, travel restrictions, factory and office closures – becomes clearer. China's GDP figures for the first quarter – due by mid-April – are likely to reflect a sharp slowdown. However, the steady return of workers to their workplaces suggests that Q2 could already see a pickup in output towards previous levels. Elsewhere, the spread of the virus has come later and should be met with the same measures deployed in China. This means that the economic impact in economies affected could drag on into the second quarter, with recovery setting in by the summer. All in all, the pick-up in global output we expected in 2020 is likely to be postponed until the second half of the year, and then extend into 2021.

Bottom line. Our investment process is based on a number of factors which have demonstrated their dependability over time. We will always determine the course of asset allocation based on the prevailing economic regime, and the current valuation, momentum and sentiment signals. In recent months, the economic regime has fluctuated between growth and slowdown, both of which represent positive environments for risk assets. Should the virus worsen, and the macro-regime deteriorate from slowdown into recession, we would of course take action. We will continue to monitor the situation very carefully.

In China, the growth rate of confirmed cases has eased



Source: SGPB, Macrobond, 28/02/2020

Past performance should not be seen as an indication of future performance. Investments may be subject to market fluctuations, and the price and value of investments and the income derived from them can go down as well as up. Your capital may be at risk and you may not get back the amount you invest.

FIXED INCOME

Short-term uncertainty means tactical cautiousness on HY

As long as the spread of Covid-19 continues to gather pace, investors will remain nervous and wary of riskier assets. While we assume growth and markets will recover in due course, uncertainty is set to linger for now. In the near term, we expect rates to stay low and riskier credits (i.e., corporate bonds) to suffer. We therefore turn tactically more cautious on High Yield.

Sovereigns

US. Coronavirus outbreak worries have pushed US sovereign yields down to fresh lows, more than reversing the rebound which easing trade tensions and better political visibility had sparked since last summer. Until the epidemic wanes, it is unlikely we will see higher US sovereign yields, as investors will keep hoarding safe assets. Investor expectations for lower policy rates have also increased in recent days for the same reason. Although there is little fundamental reason to ease monetary policy today, we expect the Fed to be on high alert in case measures to stem the spread of the virus look like jeopardising their current projections for inflation and jobs.

Eurozone. While German yields are not yet back at their historic lows, the upward swing since last summer has been reversed by spreading coronavirus fears. In the near term, safe-haven flows should keep yields low but once the epidemic begins to come under control, we would expect rates to move higher again. Like in the US, the ECB is likely to hold its course for now and would only turn more accommodative if the epidemic worsens. Peripheral bonds should remain under pressure in the near term given heightened risk aversion and the virus containment measures in Italy, where growth prospects were already weak. By year-end however, we expect the mix of ECB purchases and low political risk to spark renewed appetite for peripheral bonds.

UK. The budget stimulus promised by the new Chancellor is not likely to drive rates higher – spending will likely be focused on infrastructure, which will take time to boost growth. On the contrary, the BoE should keep a dovish bias as uncertainty mounts around EU-UK trade agreement talks. However, with long-dated yields (at 0.47%) already well below base rates, we continue to prefer short maturities.

Credit

US. Credit spreads have started to widen again on investors' coronavirus fears. Moreover, as highlighted last month, underlying issuer fundamentals have deteriorated, especially for those with the weakest ratings. The trend in ratings (i.e. the ratio of upgrades to downgrades) remains negative, and a high proportion of Investment Grade (IG) issuers are only one notch above a speculative rating. The context warrants cautiousness and we suggest further trimming High Yield (HY) exposure.

Eurozone. From a fundamental perspective, the situation is better in Europe – funding rates are lower and the ECB provides significant support as a large buyer of corporate bonds. However, credit spreads for the weakest issuers remain vulnerable in the near term given the current risk-off environment. We propose a tactical shift in HY exposure to Neutral – better opportunities will emerge once the current bout of volatility is over.

UK. Sterling corporate bonds are likely to remain correlated to their USD and EUR peers. However, UK-EU trade talks are about to start and will merit close attention given the divergent stances on level playing field requirements.

Emerging Market (EM) debt

The continued slowing of new confirmed Covid-19 cases in China is reassuring and companies are gradually trying to restart production. Fundamentally, we see no change in the ability of EM debt markets to deliver positive returns, but of course much will depend on the length and depth of the current epidemic and its impact on global economic activity. For the moment we keep an Overweight view.

Covid-19 fears have pushed US yields to record low



Source: SGPB, Bloomberg, 28/02/2020

Past performance should not be seen as an indication of future performance. Investments may be subject to market fluctuations, and the price and value of investments and the income derived from them can go down as well as up. Your capital may be at risk and you may not get back the amount you invest.

EQUITIES

Wuhan whiplash

The coronavirus epidemic has continued to depress market sentiment, especially once international contagion began to accelerate in the second half of February. China, long the epicentre of the epidemic, has seen more encouraging trends in recent days, with new cases slowing and factories ramping up output. Once the global outbreak begins to come under control, we expect markets to begin to recover.

US. US equities have followed global markets lower as coronavirus contagion spread beyond China’s borders, shedding around 12% from recent all-time highs. Such sell-offs are quite normal – in an average year, US stocks are likely to fall 5% on three occasions and once by 10% or more (data from 1949 to 2018). Moreover, equities had risen 44% since late 2018, leaving them vulnerable to selling pressure. During previous corrections sparked by virus scares, the sell-off tended to be intense but short-lived, followed by a recovery once the epidemic began to wane.

In our recent House Views reports, we have suggested a focus on defensive plays in US equities, such as the “Dividend Aristocrats”, companies which have demonstrated the ability to grow their dividends consistently over time. In terms of sectors, the sharp slowdown we expect in the near term argues for continuing to avoid more cyclically-sensitive areas like Materials, Industrials or Consumer Discretionary.

Eurozone. Euro zone bourses have not been immune to the selling pressure, down 11% from recent highs. The coronavirus fears have overwhelmed both the improvement in various measures of business and consumer confidence and the pick-up in consensus expectations for 2020 earnings growth, up to 11% from 9.9% last month. We expect these forecasts to be revised lower, given the slowdown in global and regional growth we anticipate in the first part of this year, delaying the pick-up in earnings to the second half and 2021.

This change to the near-term growth outlook means that cyclically-sensitive sectors – which we have highlighted in recent

months – are likely to face headwinds for now. Healthcare, a more defensive area, looks relatively attractive – valuations are only at a modest premium to the median over the last ten years while earnings forecasts have been ticking higher over the past 3 months.


UK. UK equities face cross-currents. On one hand, business and household confidence surveys have been bolstered by December’s decisive election result, the ensuing clarity that Brexit would go ahead and the new government’s fiscal stimulus plans. On the other, trade negotiations with the EU are likely to be extremely tense while the UK’s relatively high exposure to Energy and Materials may penalise sentiment during the coronavirus epidemic. As elsewhere, recovery should follow and we remain Neutral.

Switzerland. As highlighted in February, the Swiss franc continues to attract safe-haven inflows, raising fears that international earnings might be penalised. Nonetheless, Swiss equities have proved somewhat more resilient than other markets, no doubt helped by their heavy exposure to high-quality global leaders in sectors like Consumer Staples and Healthcare. We suggest a Neutral stance for now.

Japan. The Japanese economy may well face an unwelcome recession – Q4 2019 saw GDP drop sharply in the wake of October’s consumption tax hike while this quarter will be hit hard by the coronavirus-induced slump in Chinese demand. Moreover, this summer’s Tokyo Olympics may be postponed on virus containment grounds, delaying the hoped-for boost to tourism revenues. Nonetheless, Japanese equities have some appeal – valuations look relatively attractive, earnings are set to recover after two years of falling profits and the market boasts a solid 2.4% dividend yield.

Emerging Markets. The gradual decline in new confirmed cases of Wuhan flu has encouraged Chinese authorities to ease travel restrictions and to permit factories to reopen, albeit at reduced capacity for now. This suggests that activity should start to pick-up in Q2 after a sharp drop in the first quarter. As a result, Chinese equities have demonstrated some resilience during the recent setback in developed markets. Moreover, emerging equity markets have underperformed developed-world bourses over the past decade and valuations now look attractive in comparison.

In 2003, Chinese equities recovered quickly



Source: SGPB, Macrobond, 28/02/2020

Past performance should not be seen as an indication of future performance. Investments may be subject to market fluctuations, and the price and value of investments and the income derived from them can go down as well as up. Your capital may be at risk and you may not get back the amount you invest.

CURRENCIES

Dominated by safe-haven flows

For now, the coronavirus epidemic is likely to dominate currency trading, with safe havens like the Swiss franc close to multi-year highs. Exchange rates are only likely to revert in line with fundamentals once the crisis is perceived as having come under control.

Dollar Index. The dollar has strengthened across the board for much of this year as virus concerns drove safe-haven flows – the US was perceived as relatively immune to the spread of the epidemic and US financial assets boast a deep pool of liquidity. In recent days however, the rise of confirmed cases internationally has prompted a reassessment of this view, pushing the dollar index lower again. Moreover, rising expectations of Fed rate cuts have served to weaken the perceived yield advantage of the dollar over other currencies. As the epidemic comes under control, we expect the dollar to trade lower later this year.

EUR/USD. Measures to contain the recent virus outbreak like those implemented in Italy are likely to slow European economies as we head into the second quarter of the year. However, we do not expect ECB to cut rates, but rather to use its other tools – asset purchases, refinancing operations and so on – to ease policy if necessary. The euro remains attractively valued against the dollar on a purchasing power parity basis and the zone’s modest budget deficit and healthy balance of payments surplus stand in stark contrast to the sizeable twin deficits in the US. All in all, we expect modest upside in EUR/USD by year-end.

GBP/USD. Ever since the spectre of a “no-deal” exit from the EU faded last September, sterling has traded in a narrow band between \$1.28 and \$1.32, apart from a brief spike to \$1.35 after the December election. Looking forward, GBP/USD is likely to remain volatile. On one hand, the government’s fiscal stimulus plans should bolster medium-term growth prospects. On the other, trade negotiations with the EU and the US are likely to prove extremely difficult, raising renewed fears of a cliff-edge


Brexit at year-end. Once it becomes clear that such fears are overblown, we expect sterling to rally back above \$1.35.

USD/JPY. Over the past two years, USD/JPY has traded sideways between ¥108 and ¥112 for much of the time. On one side, safe-haven flows often bolster the yen. On the other, weak economic data – such as the Q4 GDP report in mid-February which came in well below expectations on the back of October’s consumption-tax hike – can penalise the currency. All in all, these factors should continue to keep USD/JPY range-bound this year.

EUR/CHF. The Swiss franc has strengthened since November when the Swiss National Bank (SNB) decided not to mimic the ECB’s latest cut in deposit rates. More recently, it has gained momentum as safe-haven inflows have not been met with Swiss National Bank (SNB) purchase of foreign currencies. We expect the SNB to remain on the sidelines in the face of such inflows for now and would only expect an intervention if the Swiss economy shows sustained signs of weakness.

EM currencies. The coronavirus epidemic has pushed the dollar to all-time highs against emerging market (EM) currencies. Many EM central banks have taken advantage of falling inflation levels to ease policy, with others cutting rates to mitigate the impact of outbreaks of the virus, thereby reducing their yield advantage over the dollar. At current levels, EM currencies look undervalued and oversold. However, a recovery is unlikely before the epidemic comes under control and safe-haven buying of the dollar peters out.

USD/CNY. The yuan has fluctuated in a tight band around the 7-mark versus the US dollar since the return from the lunar new year holiday, well below the levels reached after the “phase one” trade deal with the US was signed in mid-January. This weakness reflects the negative impact on Chinese growth due to the prolonged shutdown, in addition to safe-haven buying of the greenback. With Chinese factories beginning to ramp up output, we would expect the yuan to strengthen back below 7 by the second quarter.



Past performance should not be seen as an indication of future performance. Investments may be subject to market fluctuations, and the price and value of investments and the income derived from them can go down as well as up. Your capital may be at risk and you may not get back the amount you invest.

ALTERNATIVES

Rally potential in crude prices

Oil prices should recover by year-end and we suggest moving Overweight. Gold should continue to provide useful safe-haven benefits. Within hedge funds, Fixed Income Arbitrage should benefit from the bull run in rates while Event Driven is set to recover once the Wuhan flu scare abates.

Commodities

Oil

The coronavirus epidemic has continued to push oil prices lower – a combination of travel restrictions, temporary factory closures and slower growth have led specialists to slash their forecasts for 2020 demand growth. The International Energy Association has already cut its forecast from 1.2 million barrels per day (mb/d) to 825,000 mb/d and further cuts are likely. Moreover, US crude output remains at 13.0 mb/d, the highest level on record.

However, OPEC has called a meeting in early March with its allies, such as Russia, to discuss further production cuts. At present, the group – known as OPEC+ – has curbed output by 2.1 mb/d with a further 1.0 mb/d planned in an attempt to bring the market back into balance. Furthermore, with China beginning to reopen factories, we expect demand to recover to previous levels by the second half of the year.

All in all, we see Brent prices back in a \$60 and \$70 per barrel range by year-end and suggest moving Overweight.

Gold

As worries about the global spread of Wuhan flu have skyrocketed, so has the gold price, again demonstrating bullion's value as a diversifier within balanced portfolios. Gold recently touched a 7-year high at \$1659 per ounce, up from \$1517 at year-end, as investors sought safe havens.

As a result, inflows to gold ETFs have remained strong, triggering purchases of almost 100 tonnes (t) in addition to the 400t bought last year. In addition, central bank purchases represented 16.3% of aggregate demand last year, up from an average 12% in the

previous five years, as the emerging world seeks to diversify its reserves away from the US dollar. In Russia for example, the central bank's gold holding now amount to 19.9% of total reserves, just behind the 23.6% held in dollars.

As the number of new coronavirus cases in China has begun to slow, gold prices have slipped below recent highs. Nonetheless, output growth from gold mines will be negligible this year while demand from investors and central banks remains robust – we maintain our Overweight view.

Hedge funds

Long/Short (L/S) Equity

The rapid sell-off in global equity markets in recent weeks presents a challenge for L/S Equity managers – who tend to focus on corporate fundamentals – given its indiscriminate nature. However, their portfolios are of course systematically hedged with short positions, providing welcome downside protection in the current environment. We remain Neutral.

Event Driven

For now, corporate expansion plans via mergers and acquisitions are likely to go on hold, reducing deal flow for Merger Arbitrage specialists. Special Situations funds – which specialise in corporate transactions such as spin-offs – are more sensitive to market direction, leaving them vulnerable to sell-offs. However, both strategies should recover once the epidemic begins to come under control.


Fixed Income Arbitrage

As government bond yields have plumbed new depths in recent weeks, corporate bond spreads have widened as investors have begun to anticipate the risk of credit quality impairment for some highly-leveraged issuers. This environment should play to the strengths of L/S Credit managers while Fixed Income Arbitrage should benefit from the bull market in rates.

Global Macro / CTAs

The swift reversal in equity markets from February's all-time highs may prove challenging for trend-following managers (known as CTAs). However, the accompanying extension to the bull market in government bonds is likely to have provided some offset. The coronavirus outbreak creates an atypical risk environment for Global Macro funds and we suggest staying Neutral.

Gold price still has room to climb amid Covid-19



Source: SGPB, Macrobond, 28/02/2020

Past performance should not be seen as an indication of future performance. Investments may be subject to market fluctuations, and the price and value of investments and the income derived from them can go down as well as up. Your capital may be at risk and you may not get back the amount you invest.

IMPORTANT INFORMATION – PLEASE READ

Societe Generale Private Banking is a division of the Societe Generale Group operating through its head office within Societe Generale S.A. and its network (subsidiaries, branches or departments of Societe Generale S.A.) located in the countries mentioned hereafter which use the “Societe Generale Private Banking” and “Kleinwort Hambros” brands, and which distribute this document.

Subject of the document

This document has been prepared by experts of the Societe Generale Group, and more particularly of Societe Generale Private Banking division, to provide you with information relating to certain financial and economic data. The names and functions of the people who prepared this document are indicated on the first pages of the document.

This document is a marketing communication that has not been prepared in accordance with legal requirements designed to promote the independence of investment research and the investment service provider is not subject to any prohibition on dealing ahead of the dissemination of investment research.

In order to read and understand the financial and economic information included in this document, you will need to have knowledge and experience of financial markets. If this is not the case, please contact your advisor so that you no longer receive the document. Unless you do this, we shall consider that you have the necessary skills to understand this document.

Please note that this document only aims to provide simple information to help you in your investment or disinvestment decisions, and that it does not constitute a personalised recommendation. You remain responsible for any liabilities that arise. You remain responsible for the management of your assets, and you take your investment decisions freely. Moreover, the document may mention asset classes that are not authorised/marketed in certain countries, and/or which might be reserved for certain categories of investors. Therefore, should you wish to make an investment, as the case may be and according to the applicable laws, your advisor within the Societe Generale Private Banking entity of which you are a client will check your eligibility for this investment and whether it corresponds to your investment profile.

Should you not wish to receive this document, please inform your private banker in writing, and he/she will take the appropriate measures.

Conflicts of interest

This document contains the views of Societe Generale Private Banking’s experts. Societe Generale Private Banking trading desks may trade, or have traded, as principal on the basis of the expert(s) views and reports. In addition, Societe Generale Private Banking’s experts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, revenues of their entity of the Societe Generale Group and competitive factors.

As a general matter, entities within the Societe Generale Group may make a market or act as a principal trader in securities referred to in this report and can provide banking services to the companies mentioned in that document, and to their subsidiary. Entities within the Societe Generale Group may from time to time deal in, profit from trading on, hold on a principal basis, or act advisers or brokers or bankers in relation to securities, or derivatives thereof, or asset class(es) mentioned in this document.

Entities within the Societe Generale Group may be represented on the supervisory board or on the executive board of such persons, firms or entities.

Employees of the Societe Generale Group, or persons/entities connected to them, may from time to time have positions in or hold any of the investment products/ asset class(es) mentioned in this document.

Entities within the Societe Generale Group may acquire or liquidate from time to time positions in the securities and/or underlying assets (including derivatives thereof) referred to herein, if any, or in any other asset, and therefore any return to prospective investor(s) may directly or indirectly be affected.

Entities within the Societe Generale Group are under no obligation to disclose or take into account this document when advising or dealing with or on behalf of customers.

In addition, Societe Generale Private Banking may issue other reports that are inconsistent with and reach different conclusions from the information presented in this report and are under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

Societe Generale Group maintains and operates effective organisational and administrative arrangements taking all reasonable steps to identify, monitor and manage conflicts of interest. To help the Societe Generale Private Banking Entities to do this, they have put in place a management of conflicts of interest policy designed to prevent conflicts of interest giving rise to a material risk of damage to the interests of Societe Generale Private Banking's clients. For further information, Societe Generale Private Banking's clients can refer to the management of conflicts of interests policy, which was provided to them by the Societe Generale Private Banking entity of which they are clients.

General Warning

This document, which is subject to modifications, is provided for information purposes only and has no legal value.

This material has been prepared for information purposes only and is not intended to provide investment advice nor any other investment service. The document does not constitute and under no circumstances should it be considered in whole or in part as an offer, a personal recommendation or advice from any of the Societe Generale Private Banking entities, regarding investment in the asset classes mentioned therein.

Some products and services might not be available in all Société Générale Private Banking entities. Their availability in your jurisdiction may be restricted depending on local laws and tax regulations. In addition, they have to comply with Societe Generale Group Tax Code of Conduct. You should be aware that the investment to which this material relates may involve numerous risks. The amount of risk may vary but can expose you to a significant risk of losing all of your capital, including a potential unlimited loss. Accordingly these products or services may be reserved only for a certain category of eligible investors such as those who are sophisticated and familiar with these types of investment and who understand the risks involved. Furthermore, accessing some of these products, services and solutions might be subject to other conditions, amongst which is eligibility. Your private banker is available to discuss these products, services and solutions with you and to check if they can respond to your needs and are suitable for your investor profile. Accordingly, before making an investment decision, a potential investor, as the case may be and according to the applicable laws, will be questioned by his or her advisor within the Societe Generale Private Banking entity, of which the investor is a client, regarding his eligibility for the envisaged investment, and the compatibility of this investment with his investment profile and objectives.

Before any investment, the potential investor should also consult his own independent financial, legal and tax advisers in order to obtain all the financial, legal and tax information which will allow him to appraise the characteristics and the risks of the envisaged investment and the pertinence of the strategies discussed in this document, as well as the tax treatment of the investment, in the light of his own circumstances.

Prior to any investment, a potential investor must be aware of, understand and sign the related contractual and informative information, including documentation relating to risks. The potential investor has to remember that he should not base any investment decision and/or instructions solely on the basis of this document. Any financial services and investments may have tax consequences and it is important to bear in mind that the Societe Generale Private Banking entities, do not provide tax advice. The level of taxation depends on individual circumstances and such levels and bases of taxation can change. In addition, this document is not intended to provide, and should not be relied on for, accounting, tax or legal purposes and independent advice should be sought where appropriate.

Investment in some of the asset classes described in this document may not be authorised in certain countries, or may be restricted to certain categories of investors. It is the responsibility of any person in possession of this document to be aware of and to observe all applicable laws and regulations of relevant jurisdictions. This document is not intended to be distributed to people or in jurisdictions where such distribution is restricted or illegal. It is not to be published or distributed in the United States of America and cannot be made available directly or indirectly in the United States of America or to any U.S. person.

The price and value of investments and the income derived from them can go down as well as up. Changes in inflation, interest rates and exchange rates may have adverse effects on the value, price and income of investments issued in a different currency from that of the client. The simulations and examples included in this document are provided for informational and illustration purposes alone. The present information may change with market fluctuations, and the information and views reflected in this document may change. The Societe Generale Private Banking entities disclaim any responsibility for the updating or revising of this document. The document's only aim is to offer information to investors, who will take their investment decisions without relying solely on this document. The

Societe Generale Private Banking entities disclaim all responsibility for direct or indirect losses related to any use of this document or its content. The Societe Generale Private Banking entities do not offer no implicit or explicit guarantees as to the accuracy or exhaustivity of the information or as to the profitability or performance of the asset classes, countries and markets concerned.

The historical data, information and opinions provided herein have been obtained from, or are based upon, external sources that the Societe Generale Private Banking entities believe to be reliable, but which have not been independently verified. The Societe Generale Private Banking entities shall not be liable for the accuracy, relevance or exhaustiveness of this information. Information about past performance is not a guide to future performance and may not be repeated. Investment value is not guaranteed and the value of investments may fluctuate. Estimates of future performance are based on assumptions that may not be realised.

This document is confidential. It is intended exclusively for the person to whom it is given, and may not be communicated or notified to any third party (with the exception of external advisors, on the condition they themselves respect this confidentiality undertaking). It may not be copied in whole or in part without the prior written consent of the relevant Societe Generale Private Banking entity.

Specific warnings per jurisdiction

France: Unless otherwise expressly indicated, this document has been issued and distributed by Societe Generale, a French bank authorised and supervised by the *Autorité de Contrôle Prudentiel et de Résolution*, located at 4, Place de Budapest, CS 92459, 75436 Paris Cedex 09, under the prudential supervision of the *European Central Bank* (“ECB”), and under the control of the *Autorité des Marchés Financiers* (“AMF”). Societe Generale is also registered at ORIAS as an insurance intermediary under the number 07 022 493 orias.fr. Societe generale is a French Société Anonyme with its registered address at 29 boulevard Haussman, 75009 Paris, with a capital of EUR 1,066,714, 367.50 on 1st August 2019 and unique identification number 552 120 222 R.C.S. Paris. Further details are available on request or can be found at [www. http://www.privatebanking.societegenerale.fr/](http://www.privatebanking.societegenerale.fr/).

Luxembourg: This document has been distributed in Luxembourg by Societe Generale Bank & Trust (“SGBT”), a credit institution which is authorised and regulated by the *Commission de Surveillance du Secteur Financier* (“CSSF”) under the prudential supervision of the *European Central Bank* (“ECB”), and whose head office is located at 11 avenue Emile Reuter – L 2420 Luxembourg. Further details are available on request or can be found at www.sgbt.lu. No investment decision whatsoever may result from solely reading this document. SGBT accepts no responsibility for the accuracy or otherwise of information contained in this document. SGBT accepts no liability or otherwise in respect of actions taken by recipients on the basis of this document only and SGBT does not hold itself out as providing any advice, particularly in relation to investment services. The opinions, views and forecasts expressed in this document (including any attachments thereto) reflect the personal views of the author(s) and do not reflect the views of any other person or SGBT unless otherwise mentioned. SGBT has neither verified nor independently analysed the information contained in this document. The CSSF has neither verified nor analysed the information contained in this document.

Monaco: The present document has been distributed in Monaco by Société Générale Private Banking (Monaco) S.A.M., located 13, 15 Bd des Moulins, 98000 Monaco, Principality of Monaco, governed by the *Autorité de Contrôle Prudentiel et de Résolution* and the *Commission de Contrôle des Activités Financières*. The Financial products marketed in Monaco can be reserved for qualified investors in accordance with Law No. 1339 of 07/09/2007 and Sovereign Ordinance No 1.285 of 10/09/2007. Further details are available upon request or on www.privatebanking.societegenerale.mc.

Switzerland: This document has been communicated in Switzerland by Société Générale Private Banking (Suisse) SA (« SGPBS »), whose head office is located at rue du Rhône 8., CH-1204 Geneva. SGPBS is a bank authorized by the *Swiss Financial Market Supervisory Authority* (“FINMA”). Further details are available on request or can be found at www.privatebanking.societegenerale.ch.

This document (i) does not provide any opinion or recommendation about a company or a security, or (ii) has been prepared outside of Switzerland for the « Private banking ». Therefore, the Directives of the Swiss Bankers Association (SBA) on the Independence of Financial Research do not apply to this document.

This document has not been prepared by SGPBS. SGPBS has neither verified nor independently analyzed the information contained in this document. SGPBS accepts no responsibility for the accuracy or otherwise of information contained in this document. The opinions, views and forecasts expressed in this document reflect the personal views of the relevant author(s) and shall not engage SGPBS' liability.

This document is not a prospectus within the meaning of articles 652a and 1156 of the Swiss Code of Obligations.

This document is issued by the following companies in the Kleinwort Hambros Group under the brand name Kleinwort Hambros:

United Kingdom: SG Kleinwort Hambros Bank Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. The firm reference number is 119250. The company is

incorporated in England and Wales company registration under number 964058 and its registered address is 5th Floor, 8 St James's Square, London, England, SW1Y 4JU.

Channel Islands: Kleinwort Hambros is the brand name of SG Kleinwort Hambros Bank (CI) Limited, which is regulated by the Jersey Financial Services Commission for banking, investment, money services and fund services business. The company is incorporated in Jersey under company registration number company registration 2693 and its registered address is PO Box 78, SG Hambros House, 18 Esplanade, St Helier, Jersey JE4 8PR.

SG Kleinwort Hambros Bank (CI) Limited – Guernsey Branch is regulated by the Guernsey Financial Services Commission for banking, investment and money services business. Its address is PO Box 6, Hambro House, St Julian's Avenue, St Peter Port, Guernsey, GY1 3AE. The company (including the branch) is also authorised and regulated by the UK Financial Conduct Authority in respect of UK regulated mortgage business and its firm reference number is 310344. The Company (including the branch) is not authorised or regulated by the UK Financial Conduct Authority for accepting UK bank deposits nor is it permitted to hold deposits in the UK.

Kleinwort Hambros is the brand name of SG Kleinwort Hambros Trust Company (CI) Limited, which is regulated by the Jersey Financial Services Commission in the conduct of trust company business and fund services business and by the Guernsey Financial Services Commission in the conduct of fiduciary services business. The company is incorporated in Jersey under company registration number 4345 and its registered address is SG Hambros House, PO BOX 197, 18 Esplanade, St Helier, Jersey, JE4 8RT. Its address in Guernsey is PO Box 86, Hambro House, St Julian's Avenue, St Peter Port, Guernsey, GY1 3ED.

This document has not been authorized or reviewed by the JFSC or FCA.

Gibraltar: SG Kleinwort Hambros Bank (Gibraltar) Limited is authorised and regulated by the Gibraltar Financial Services Commission for the conduct of banking, investment and insurance mediation business and its firm reference is 419436. The company is incorporated in Gibraltar under company registration number 01294 and its registered address is 32 Line Wall Road, Gibraltar.

Kleinwort Hambros is part of Societe Generale Private Banking, which is part of the wealth management arm of the Societe Generale Group. Societe Generale is a French Bank authorised in France by the Autorité de Contrôle Prudentiel et de Résolution, located at 4, Place de Budapest, CS 92459, 75436 Paris Cedex 09 and under the prudential supervision of the European Central Bank. It is also authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority.

Further information on the Kleinwort Hambros Group including additional legal and regulatory details can be found at: www.kleinworthambros.com

<http://www.privatebanking.societegenerale.com>

© Copyright Societe Generale Group 2019. All rights reserved. Any unauthorised use, duplication, redistribution or disclosure in whole or in part is prohibited without the prior consent of Societe Generale. The key symbols, Societe Generale, Societe Generale Private Banking and Kleinwort Hambros are registered trademarks of Societe Generale. All rights reserved.

Societe Generale

SA Capital EUR 1,009,897,173.75 at 31 December 2018

Registered under Paris RCS N°552 120 222

Societe Generale Private Banking

Tour Société Générale

17, Cours Valmy

75886 – Paris Cedex 18

France

<http://www.privatebanking.societegenerale.com>



Societe Generale is a member of Ecofolio and participates in the financing of paper recycling. This document was printed on paper from sustainably managed forests.